Steven Holtzman

Steven H.
Holtzman founded DNX Corp.
in 1986, where he worked as Director & Executive Vice President from 1986 to 1994, Infinity Pharmaceuticals, Inc. in 1995, where he worked as Non-Executive Chairman from 2011 to 2012, and Shoreline Biosciences, Inc. in 2020, where he is working as Director from 2020.
Dr. Holtzman also founded Biotechnology Innovation Organization, where he is working as Director from 2010.
Dr. Holtzman also currently works at Manifold Biotechnologies, Inc., as Executive Chairman from 2024, Hangzhou Qihan Biotech Co., Ltd., as Chairman from 2019, CAMP4 Therapeutics Corp., as Independent Director from 2025, Molecular Partners, Inc., as Director, Berklee College of Music, as Trustee, Georgetown University, as Trustee, and Formation Bio Inc, as strategic advisor from 2021.
Dr. Holtzman also formerly worked at Decibel Therapeutics, Inc., as President, Chief Executive Officer & Director from 2016 to 2020, Anadys Pharmaceuticals, Inc., as Chairman in 2011, The Hastings Center, as Vice Chairman from 1999 to 2010, Archemix Corp., as Director, Satori Pharmaceuticals, Inc., as Director from 2009 to 2010, Visterra, Inc., as Director, Amsterdam Molecular Therapeutics (AMT) Holding NV, as Director-Supervisory Board in 2010, Warp Drive Bio, Inc., as Director, Ataxion, Inc., as Director, PMV Pharmaceuticals, Inc., as Director, The Sync Project, Inc., as Director, Humatics Corp., as Director, Molecular Partners AG, as Independent Non-Executive Director from 2014 to 2026, Biogen, Inc., as Executive Vice President-Corporate Development from 2011 to 2016, Stromedix, Inc., as President, Millennium Pharmaceuticals, Inc., as Chief Business Officer from 1994 to 2001, and Hastings Center for Ethics & Life Science, as Trustee from 1999 to 2008.
Dr. Holtzman received his undergraduate degree in 1976 from Michigan State University and undergraduate degree in 1979 from Corpus Christi College.